Clinical Trials on Seasonal Influenza in Germany

Total 164 results

Ology Bioservices

Completed

Phase 3 Immunogenicity and Safety Study of an Inactivated H5N1 Influenza Vaccine (Whole Virion, Vero Cell Derived)

Influenza

Germany, Austria
Abbott Biologicals
Quintiles, Inc.

Completed

Annual Study to Investigate Inactivated Subunit Influenza Vaccine Due to New Virus Strains for the 09/10 Season

Influenza

Belgium, Germany
GlaxoSmithKline

Completed

A Study to Evaluate the Safety and Immunogenicity of GSK Biologicals' Seasonal Influenza Vaccine in Adults

Influenza

Germany
GlaxoSmithKline

Completed

A Study for Evaluation of Immunogenicity and Reactogenicity of FluarixTM / Influsplit SSW® 2009/2010 in Adults

Influenza

Germany
Abbott Biologicals
Quintiles, Inc.

Completed

Annual Study to Investigate Inactivated Subunit Influenza Vaccine Due to New Virus Strains for the 2010/2011 Season

Influenza

Belgium, Germany
GlaxoSmithKline

Completed

A Study for Evaluation of Immunogenicity and Reactogenicity of Fluarix™ / Influsplit SSW® 2008/2009 in Adults

Influenza

Germany
GlaxoSmithKline

Completed

Immunogenicity and Reactogenicity of Fluarix™ (Influsplit SSW®) 2007/2008 in People 18 Years Old or Above

Influenza

Germany
University of Rostock
Sanofi Pasteur, a Sanofi Company; Klinikum Ernst von Bergmann Potsdam; Klinikum...

Unknown

Burden of Influenza at Emergency Department (ED) Level in European Countries

Influenza, Human

Germany
Ology Bioservices

Completed

Safety and Immunogenicity Study of an Inactivated Influenza Vaccine (Whole Virion, Vero Cell Derived)

Influenza

Germany, Austria
Ology Bioservices

Completed

Comparison of the Safety and Immune Response of Three Different Lots of an Influenza Vaccine Made by a New Manufacturing Process With a Vaccine Made by the Traditional Manufacturing Process for Season 2004/2005

Influenza

Austria, Germany
Solvay Pharmaceuticals

Completed

Annual Study to Investigate Influenza Vaccine Due to New Virus Strains for the 2007/2008 Influenza Season in Europe

Healthy Volunteers

Belgium, Germany
GlaxoSmithKline

Completed

Study to Evaluate the Immunogenicity and Safety of an Investigational Influenza (H1N1 Influenza Virus) Vaccine in Adults, Using Two Different Manufacturing Processes

Influenza

Germany
Novartis Vaccines

Completed

Immunogenicity, Safety and Tolerability of Two Doses of Adjuvanted and Non-adjuvanted Swine Origin A/H1N1 Monovalent Influenza Vaccine (Egg-Derived) in Healthy Subjects From 6 Months to 17 Years of Age

Pandemic Influenza

Netherlands, Belgium, Chile, Dominican Republic, Germany
Stallergenes Greer
Quintiles, Inc.; Cenduit LLC; Aptuit Inc.; PHT Corporation

Completed

Efficacy and Safety Study of a Sublingual Immunotherapy Solution to Treat Patients Suffering From Birch Pollen Allergic Rhinoconjunctivitis

Hypersensitivity | Allergic Rhinitis | Allergic Conjunctivitis | Seasonal Allergy

Czech Republic, Denmark, Estonia, Finland, France, Germany, Latvia, Lithuania, Poland, Slovakia, Sweden
Novartis Vaccines

Completed

Safety and Immunogenicity of One Dose of Seasonal Trivalent Influenza Virus Vaccine (TIVf, Purified Surface Antigen, Inactivated, Egg Derived) in Adults Aged 18 Years and Above

Influenza | Human

Germany
GlaxoSmithKline

Completed

Immunogenicity and Safety Study of GlaxoSmithKline (GSK) Biologicals' Influenza Vaccine, Fluarix®/Influsplit SSW® (2013/2014 Season), in Adults 18 Years of Age and Older

Influenza

Germany
Novartis Vaccines

Completed

Safety and Immunogenicity of a Cell Derived Subunit Trivalent Nonadjuvated Influenza Study Vaccine in Adults Aged 18 Years and Above

Influenza

Germany
University Children's Hospital, Wuerzburg
GlaxoSmithKline; University of Wuerzburg

Unknown

Surveillance of Influenza in Paediatric Intensive Care Units in Bavaria

Influenza | Acute Respiratory Infection

Germany
GlaxoSmithKline

Completed

Safety Study of Pandemic Candidate Influenza Vaccines in the Elderly Population

Influenza | Influenza Vaccines

Germany
Sanofi Pasteur, a Sanofi Company

Completed

Immunogenicity Study of the Influenza Vaccine in Adults

Influenza | Orthomyxoviridae Infections

Belgium, Germany, Switzerland
GlaxoSmithKline

Completed

Safety & Immunogenicity of an Alternative Immunization Schedule of GSK Bio's Pandemic Influenza Vaccine (GSK1119711A)

Influenza | Influenza Vaccines

Germany
Sanofi Pasteur, a Sanofi Company

Completed

Safety Surveillance of VaxigripTetra® and Efluelda® Influenza Vaccines in Europe During the Influenza Season 2022/23

Influenza (Healthy Volunteers)

Germany, Finland
Philipps University Marburg Medical Center

Completed

Do Videos That Aim to Optimize Expectations Alter the Effectivess of PMR?

Control Group | Experimental Group 1 (Video Personal Expert) | Experimental Group 2 (Video Factual Expert)

Germany
Sanofi Pasteur, a Sanofi Company

Completed

Safety Surveillance of VaxigripTetra® and Efluelda® Influenza Vaccines in Europe During the Influenza Season 2021/22

Influenza (Healthy Volunteers)

Germany, Finland
Harding Center for Risk Literacy

Recruiting

Equity Evaluation of Fact Boxes on Informed COVID-19 and Influenza Vaccination Decisions - Study Protocol

COVID-19 | Influenza

Germany
Klinikum Bayreuth GmbH

Completed

Detection of Influenza or SARS-CoV-2 Infection by IMS of Nasal Air Sampling

Influenza

Germany
GlaxoSmithKline

Completed

Evaluation of the Immune Response and the Safety of a Pandemic Influenza Candidate Vaccine (H1N1)

Influenza

Germany
Ology Bioservices

Completed

Safety and Immunogenicity Study of an Inactivated Influenza Vaccine (Split Virus, Vero Cell Derived)

Influenza

Austria, Germany, Poland
Allergopharma GmbH & Co. KG

Completed

Safety and Efficacy of Specific Immunotherapy With an Aluminium Hydroxide-adsorbed Allergoid Preparation of Birch Pollen Allergens

Pollen Allergy

Germany
Charite University, Berlin, Germany

Terminated

Action of Caffeinated and Decaffeinated Espresso on Autonomic Function

Influence of Espresso on Heart Rate Variability

Germany
Seqirus
Novartis Vaccines

Completed

Safety and Immunogenicity of Two Doses of aH5N1 Vaccine in Adult and Elderly Subjects With and Without Immunosuppressive Conditions *aH5N1:Monovalent H5N1 Influenza Vaccine

Influenza | Influenza, Human | Influenza A Virus, H5N1 Subtype | Flu, Human | Flu, Avian

Australia, Germany, Italy
Allergopharma GmbH & Co. KG

Completed

Safety and Efficacy of Grass Pollen Allergoid in the Treatment of Allergic Rhinoconjunctivitis

Grass Pollen Allergy

Germany
Allergopharma GmbH & Co. KG

Completed

Safety and Efficacy of a Sublingual Specific Immunotherapy With an Extract of a Six Grass Pollen Mixture

Grass Pollen Allergy

Germany
Sanofi Pasteur, a Sanofi Company

Completed

Study to Assess the Immune Response and the Safety Profile of a High-Dose Quadrivalent Influenza Vaccine (QIV-HD) Compared to a Standard-Dose Quadrivalent Influenza Vaccine (QIV-SD) in Europeans Adults 60 Years of Age and Older

Healthy Volunteers | Influenza Immunization

France, Belgium, Germany, Italy, Netherlands, Poland
Allergopharma GmbH & Co. KG

Completed

Safety and Efficacy of Recombinant Birch Pollen Allergen in the Treatment of Allergic Rhinoconjunctivitis

Birch Pollen Allergy

Germany
GlaxoSmithKline

Terminated

Study to Evaluate the Immune Response and the Safety of Fluarix TM/ Influsplit SSW® 2010/2011 or Pandemrix TM

Influenza

Germany
Allergopharma GmbH & Co. KG

Completed

Specific Immunotherapy With Recombinant Birch Pollen Allergen rBet v1-FV

Birch Pollen Allergy

Germany
GlaxoSmithKline

Completed

Study to Evaluate the Safety and Immunogenicity of Pandemic Monovalent (H5N1) Influenza Vaccines (Whole Virus Formulation) in Adults 18 and 60 Years of Age

Influenza

Germany
GlaxoSmithKline

Completed

Study to Evaluate the Immunogenicity and Safety of an Investigational Influenza Vaccine (H1N1) in Children

Influenza

Germany
GlaxoSmithKline

Completed

Study to Evaluate Immunological Equivalence Between Two Investigational Influenza Vaccines in Adults (H1N1)

Influenza

France, Germany
GlaxoSmithKline

Completed

Enhanced Safety Surveillance of GlaxoSmithKline's (GSK's) Quadrivalent Seasonal Influenza Vaccines During the 2018/19 Influenza Season

Influenza, Human

Germany, Spain, Belgium
GlaxoSmithKline

Completed

A 5-way Treatment Period Trial of Single Doses of Intranasal GSK256066 in Patients With Rhinitis

Rhinitis, Allergic, Seasonal

Germany
GlaxoSmithKline

Completed

Single and Repeat Dose First Time in Human Study for an Intranasal H1/H3 Dual Antagonist in Healthy Male Subjects

Rhinitis, Allergic, Seasonal

Germany
GlaxoSmithKline

Completed

Immuno & Reacto of TF Trivalent Influenza Split Vaccine 2003/04 or of Std Formulation Influsplit SSW®/Fluarix™ 2003/04

Influenza

Germany
Boehringer Ingelheim

Completed

Randomized, Placebo Controlled, Crossover Study in an Environmental Challenge Chamber to Assess Safety & Efficacy of Three Oral Doses of BI 671800 Versus Fluticasone Propionate and Montelukast in Sensitive Seasonal Allergic Rhinitis Patients Out of Season

Asthma | Rhinitis, Allergic, Seasonal

Germany
GlaxoSmithKline

Completed

Allergen Challenge Chamber Study With Single Dose Oral GSK835726 Compared With Placebo

Rhinitis, Allergic, Seasonal

Germany
Sandoz

Completed

Prospective, Randomized, Multinational, Multicenter, Double-blind, Placebo and Active Controlled Trial in 4 Parallel-groups of Patients Suffering From Seasonal Allergic Rhinitis

Seasonal Allergic Rhinitis

Bulgaria, Germany, Poland, Moldova, Republic of
Johann Wolfgang Goethe University Hospital

Completed

Regulatory T-cells After Subcutaneous Immunotherapy (RTCAS)

Grass Pollen Allergy | Specific Immunotherapy

Germany
GlaxoSmithKline

Completed

Study on the Immunogenicity and Tolerability of Influsplit SSW® 2005/2006 in Children Aged 6 - 13 Years

Influenza

Germany
Stallergenes Greer

Active, not recruiting

Safety and Efficacy of STALORAL® Birch 300 IR in a Paediatric Population With Birch Pollen-induced ARC w/o Asthma (YOBI)

Allergic Rhinoconjunctivitis | Birch Pollen Allergy

Germany

3

Subscribe